Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.

IF 11.5 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Biomarker Research Pub Date : 2025-02-04 DOI:10.1186/s40364-025-00736-8
Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang
{"title":"Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.","authors":"Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang","doi":"10.1186/s40364-025-00736-8","DOIUrl":null,"url":null,"abstract":"<p><p>Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies. However, realizing broader therapeutic applications of engineered T cells in other diseases requires further exploration in clinical investigations. In this review, we highlight recent advances in the engineering of T cells in non-oncology areas, including autoimmune and inflammatory diseases, infections, fibrosis, hemophilia, and aging. Chimeric antigen receptor immunotherapy has shown good outcomes in non-oncology areas, but many challenges remain in improving its safety and efficacy and and expanding its application to the treatment of non-oncological diseases.</p>","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"13 1","pages":"23"},"PeriodicalIF":11.5000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792665/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40364-025-00736-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies. However, realizing broader therapeutic applications of engineered T cells in other diseases requires further exploration in clinical investigations. In this review, we highlight recent advances in the engineering of T cells in non-oncology areas, including autoimmune and inflammatory diseases, infections, fibrosis, hemophilia, and aging. Chimeric antigen receptor immunotherapy has shown good outcomes in non-oncology areas, but many challenges remain in improving its safety and efficacy and and expanding its application to the treatment of non-oncological diseases.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
工程化T细胞免疫治疗自身免疫和其他非肿瘤疾病的进展。
使用表达嵌合抗原受体的工程化T细胞的过继免疫疗法在治疗血液系统恶性肿瘤患者中显示出显着的成功。然而,要实现工程化T细胞在其他疾病中的更广泛的治疗应用,还需要在临床研究中进一步探索。在这篇综述中,我们重点介绍了T细胞工程在非肿瘤领域的最新进展,包括自身免疫性和炎症性疾病、感染、纤维化、血友病和衰老。嵌合抗原受体免疫疗法在非肿瘤领域已显示出良好的效果,但在提高其安全性和有效性,扩大其在非肿瘤疾病治疗中的应用方面仍存在许多挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Biomarker Research
Biomarker Research Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
15.80
自引率
1.80%
发文量
80
审稿时长
10 weeks
期刊介绍: Biomarker Research, an open-access, peer-reviewed journal, covers all aspects of biomarker investigation. It seeks to publish original discoveries, novel concepts, commentaries, and reviews across various biomedical disciplines. The field of biomarker research has progressed significantly with the rise of personalized medicine and individual health. Biomarkers play a crucial role in drug discovery and development, as well as in disease diagnosis, treatment, prognosis, and prevention, particularly in the genome era.
期刊最新文献
tRNA modifications in cancer: from molecular mechanisms to clinical translation. Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysis. TUSC7 expression and mutational profile define its potential as a diagnostic and therapeutic biomarker in non-small cell lung cancer. The molecular landscape of the C1498 murine acute myeloid leukemia cell line. Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1